Document:

exv10w3

Exhibit 10.3

***Text Omitted and Filed Separately with the Securities and Exchange Commission.

Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2.

	 	 	 

	

	 	28903 North Avenue Paine, Valencia, California    91355      USA

61 South Paramus Road, Paramus, New Jersey 07652      USA

One Casper Street, Danbury, Connecticut 06810      USA

www.mannkindcorp.com

N.V. Organon

Kloosterstraat 6,

5349 AB Oss,

The Netherlands

Dear Sirs:

Supply Agreement (the “Supply Agreement”) made as of the 7th of November 2007, between
MannKind Corporation, a Delaware corporation (“MannKind”), with its principal office and place of
business at 28903 North Avenue Paine, Valencia, CA 91355, U.S.A., and N.V. Organon, a Dutch company
(“Organon”) with its principal office and place of business at Kloosterstraat 6, 5349 AB OSS, The
Netherlands (each of MannKind and Organon, a “Party” and together, the “Parties”).

A dispute has arisen between the Parties relating to the Supply Agreement (the “Dispute”). The
Parties have settled their differences and have agreed terms for the full and final settlement of
the Dispute. They wish to record those terms of settlement (including the termination of the Supply
Agreement), on a binding basis, in this letter agreement (“Letter Agreement”).

Agreed terms

	1.	 	Interpretation
	 
	 	 	Capitalised terms used but not defined in this Letter Agreement shall have the meaning
given to them in the Supply Agreement.
	 
	2.	 	Effect of this Letter Agreement
	 
	 	 	The Parties hereby agree that this Letter Agreement shall immediately be fully and
effectively binding on them.
	 
	3.	 	Payment, Delivery and Acceptance
	 
	3.1	 	The Supply Agreement is terminated. Notwithstanding such termination, the
provisions of the Supply Agreement explicitly referred to herein, as well as all provisions
designated to survive termination pursuant to Section 11.5 of the Supply Agreement, shall
survive this termination and remain in effect.
	 
	3.2	 	MannKind shall pay to Organon the total sum of US$16 million, divided into two
installments payable by way of bank transfer as follows:

	 
		 	(a) the amount of US$8 million to be paid within two days of
MannKind’s receipt of the
First Shipment (as defined in Section 3.3(a) below); And
	 
		 	(b) the amount of US$8 million to be paid within two days of
MannKind’s receipt of the
Second Shipment (as defined in Section 3.3(b) below).

 

 

	3.3	 	Organon shall manufacture and supply to MannKind’s Danbury, Connecticut facility a total of
[...***...] of Product manufactured in
accordance with the shelf life requirements of the Supply Agreement and divided into two
shipments deliverable as follows:
	 
		 	(a) A shipment of approximately [...***...] of Product to arrive at MannKind’s Danbury,
Connecticut Facility on 28 June 2011 (the “First Shipment”); and
	 
		 	(b) A shipment of the balance of the total of [...***...] of Product to be shipped from
Organon’s facility in France as soon as practicable following Organon’s receipt of the
payment from MannKind pursuant to Section 3.2(a) above (the “Second Shipment”). Organon shall
deliver the Second Shipment to MannKind’s Danbury, Connecticut facility as soon as
practicable following such Second Shipment’s having received all regulatory, customs, or FDA
clearances required for shipment into and within the United States, provided, however, that
Organon shall provide MannKind reasonable notice in advance of the planned delivery date and
provided further that such delivery date shall be extended as necessary to ensure that
delivery does not occur on any statutory holiday, a weekend, a Monday or a Friday. To
facilitate Organon’s delivery obligations under this Section 3.3(b), MannKind hereby agrees
to provide Organon with a Letter of Intended Use in the form attached hereto as Schedule A
and revised by MannKind as may be necessary in order to meet government/regulatory
requirements. For the avoidance of doubt, it shall be MannKind’s obligation to provide a
Letter of Intended Use that satisfies all government/regulatory requirements.
	 
	3.4	 	Organon shall bear the risk of loss for the Product until delivery to such designated
facility at which time title to the Product and the risk of loss shall pass to MannKind.
	 
	3.5	 	Each shipment of the Product shall be accompanied by accurate and complete documents
including, but not limited to, relevant certificates of analysis and certificates of
compliance.
	 
	3.6	 	The provisions of clause 6.4 (“Inspection, Acceptance and Rejection”) and clause 6.5
(“Expert”) of the Supply Agreement shall apply to each delivery of Product under this Letter
Agreement.
	 
	3.7	 	Product supplied by Organon hereunder shall conform to the Specification set forth in Exhibit
A to the Supply Agreement and the warranty set forth in clause 3.8 of this Letter Agreement.
Organon shall perform quality control testing and quality oversight on the Product to be
delivered to MannKind hereunder.
	 
	3.8	 	Organon represents and expressly warrants that the Product provided under this Letter
Agreement shall conform to the Specifications, including the Quality/Technical Agreement,
shall be in compliance with all applicable laws and regulations, and free from defect, claim,
encumbrance or lien. If and to the extent the corresponding event is not governed by clause
3.6 of this Letter Agreement, upon any breach of the warranty Organon shall at Organon’s sole
expense promptly (and in no event longer than ninety (90) calendar days) correct, at no cost
to MannKind, and at MannKind’s request, any such breach by replacement of the Product that did
not conform to such warranty and shall provide technical assistance to MannKind to address the
Product non-conformity issues. Any replacement shall be considered a new Product for purposes
of this clause 3.8.
	 
	 	 	Organon represents and warrants that it has and shall at all times throughout the term of
this Agreement have, whether by right, title, interest, including by license or otherwise,
the Intellectual Property Rights that are required to use, manufacture, market, offer to
sell, sell, import and export the Product in accordance with the terms of this Letter
Agreement and that this Letter Agreement shall not infringe third party rights.

***Confidential Treatment Requested

2

 

	 	 	EXCEPT AS EXPRESSLY PROVIDED HEREIN, ORGANON MAKES NO OTHER WARRANTIES, EXPRESS OR IMPLIED,
AS TO THE QUALITY OR FITNESS FOR PURPOSE OF THE PRODUCT SUPPLIED TO MANNKIND.
	 
	3.9	 	MannKind shall only use the Product for End Product in the Territory.
	 
	4.	 	Release
	 
	 	 	This Letter Agreement is in full and final settlement of, and each party hereby releases and
forever discharges, all and/or any actions, claims, rights, demands and set-offs, whether in
this jurisdiction or any other, whether or not presently known to the parties or to the law,
and whether in law or equity, that it, its parent, subsidiaries, assigns, transferees,
representatives, principals, agents, officers and directors or any of them ever had, may have
or hereafter can, shall or may have against the other party or any other of its parent,
subsidiaries, assigns, transferees, representatives, principals, agents, officers or
directors arising out of or connected with:
	 
		 	(a) the Dispute;
	 
		 	(b) the underlying facts relating to the Dispute;
	 
		 	(c) any agreement between or act by the parties, their parents, subsidiaries, assigns,
transferees, representatives, principals, agents, officers or directors, or any of them; and
	 
		 	(d) any other matter arising out of or connected with the relationship between the parties
(including the Supply Agreement).
	 
	 	 	(Collectively the “Released Claims”).
	 
	5.	 	Agreement Not to Sue
	 
	 	 	Except as necessary to enforce its rights under this Letter Agreement, each Party agrees, on
behalf of itself and on behalf of its parent, subsidiaries, assigns, transferees,
representatives, principals, agents, officers or directors, not to sue, commence, voluntarily
aid in any way, prosecute or cause to be commenced or prosecuted against the other party or
its parent, subsidiaries, assigns, transferees, representatives, principals, agents, officers
or directors, any action, suit or other proceeding concerning the Released Claims, in this
jurisdiction or any other.
	 
	6.	 	Costs
	 
	 	 	The Parties shall each bear their own costs (including but not limited to legal costs) in
relation to the Dispute and this Letter Agreement.
	 
	7.	 	Warranties and Authority
	 
	7.1	 	Each Party warrants and represents that it has not sold, transferred, assigned or otherwise
disposed of its interest in the Released Claims.
	 
	7.2	 	Each Party warrants and represents to the other with respect to itself that it has the full
right, power and authority to execute, deliver and perform this Letter Agreement.
	 
	8.	 	Indemnities
	 
	 	 	Each Party hereby indemnifies, and shall keep indemnified, the other party against all costs
and damages (including the entire legal expenses of the parties) incurred in all future
actions, claims and proceedings in respect of any of the Released Claims which they may bring
against the other party or its parent, subsidiaries, assigns, transferees, representatives,
principals, agents, officers or directors.

3

 

	9.	 	No Admission
	 
	 	 	This Letter Agreement is entered into in connection with the compromise of disputed matters
and in the light of other considerations. It is not, and shall not be represented or
construed as, an admission of liability or wrongdoing on the part of either Party to this
Letter Agreement or any other person or entity.
	 
	10.	 	Severability
	 
	 	 	If any provision of this Letter Agreement is found to be void or unenforceable, that
provision shall be deemed to be deleted from this Letter Agreement and the remaining
provisions of this Letter Agreement shall continue in full
force and effect and the Parties shall use their respective reasonable endeavours to procure
that any such provision is replaced by a provision which is valid and enforceable, and which
gives effect to the spirit and intent of this Letter Agreement.
	 
	11.	 	Entire Agreement
	 
	 	 	This Letter Agreement, together with the provision of the Supply Agreement and Quality
Agreement referenced herein, constitutes the entire understanding and agreement between the
Parties in relation to the subject matter of this Letter Agreement.
	 
	 	 	Each Party acknowledges that it has not entered into this Letter Agreement in reliance wholly
or partly on any representation or warranty made by or on behalf of the other party (whether
orally or in writing) other than as expressly set out in this Letter Agreement.
	 
	12.	 	Confidentiality
	 
	 	 	The terms of this Letter Agreement, and the substance of all negotiations in connection with
it, are confidential to the Parties and their advisers, who shall not disclose them to, or
otherwise communicate them to, any third party other than:
	 
		 	(a) to the Parties’ respective auditors, insurers and lawyers on terms which preserve
confidentiality;
	 
		 	(b) pursuant to an order of a court of competent jurisdiction or pursuant to any proper order
or demand made by any competent authority or body where they are under a legal or regulatory
obligation to make such a disclosure; and
	 
		 	(c) as far as necessary to implement and enforce any of the terms of this Letter Agreement.
	 
	 	 	The Parties are entitled to confirm the fact of, but not the terms of, settlement of the
Dispute.
	 
	13.	 	Governing Law and Dispute Resolution
	 
		 	13.1 This Letter Agreement shall be governed by, and construed in accordance with English
law.
	 
		 	13.2 Any controversy or claim arising out of or relating to this Letter Agreement, or the
breach thereof, shall be settled by arbitration by a sole arbitrator administered by the
American Arbitration Association under its Commercial Arbitration Rules, and judgment on the
award rendered by the arbitrator may be entered in any court having jurisdiction thereof.
Such arbitration shall be conducted in the English language in New York City.
	 
	14.	 	Contracts (Rights of Third Parties) Act 1999
	 
	 	 	No other person who is not a party to this Letter Agreement shall have any rights, whether
under the Contract (Rights of Third Parties) Act 1999 or otherwise, to enforce any terms of
this Letter Agreement.

4

 

	15.	 	Co-operation
	 
	 	 	The Parties shall deliver or cause to be delivered such instruments and other documents at
such times and places as are reasonably necessary or desirable, and shall take any other
action reasonably requested by the other Party for the purpose of putting this Letter
Agreement into effect, including MannKind’s provision of appropriate purchase orders and a
Letter of Intended Use in the form attached hereto as Schedule A, revised by MannKind as may
be necessary to allow the Product to receive customs/FDA or other regulatory clearance. The
parties shall fully cooperate with each other to provide feedback, comments, questions or
other communications, if any, received from any governmental agency or authority with respect
to any documents or requirements necessary for importation of the Product into the United
States and shipment within the United States.
	 
	16.	 	Counterparts
	 
	 	 	This Letter Agreement may be signed in any number of counterparts, each of which, when
executed and delivered, shall be an original and all of which together evidence the same
Letter Agreement.
	 
	17.	 	Variation
	 
	 	 	Any variation of this Letter Agreement shall be in writing and signed by or on behalf of each
party.

IN WITNESS WHEREOF, the Parties hereto have this day caused this Letter Agreement to be executed by
their duly authorized officers.

	 	 	 	 	 	 	 

	N.V. Organon	 	MannKind Corporation
	 
	 	 	 	 	 	 
	By:

	 	/s/ Dr. Ir. Jan Smook
	 	By:
	 	/s/ Hakan Edstrom
	 

	 	 
	 	 	 	 
	 

	 	Name: Dr. Ir. Jan Smook
	 	 	 	Name: Hakan Edstrom
	 

	 	Title: Vice President Manufacturing
	 	 	 	Title: President & COO
	 

	 	Date: 24 June 2011
	 	 	 	Date: 6/23/2011
	 
	 	 	 	 	 	 
	By:

	 	/s/ J.H.M. Pluymen
 

	 	 	 	 
	 

	 	Name: J.H.M. Pluymen	 	 	 	 
	 

	 	Title: Chairman of the Board	 	 	 	 
	 

	 	Date: 24 June 2011	 	 	 	 

5exv10w1

Exhibit 10.1

SEPARATION AGREEMENT

          THIS SEPARATION AGREEMENT (this “Agreement”) is made and entered into effective as of
August 3, 2011 (the “Effective Date”), by and between Exterran Holdings, Inc., a Delaware
corporation (the “Company”) and Ernie L. Danner (the “Executive”).

W I T N E S S E T H:

          WHEREAS, the Executive is employed as the President and Chief Executive Officer of the Company
and serves as a member of the Board of Directors of the Company (the “Board”); and

          WHEREAS, the Company and the Executive mutually desire to arrange for the Executive’s
separation from employment with the Company and all Company affiliates and resignation from the
Board; and

          WHEREAS, the Company has agreed to pay the Executive certain severance benefits in exchange
for the Executive’s promises and covenants contained herein;

          NOW, THEREFORE, in consideration of the premises, the terms and provisions set forth herein,
the mutual benefits to be gained by the performance thereof and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto
agree as follows:

     1. Termination. Effective as of October 31, 2011 or such other (i) earlier date
after the Effective Date as determined by the Board, in its sole discretion, but in no event prior
to October 10, 2011, or (ii) later date mutually agreed to by the Board and the Executive, but in
no event later than December 31, 2011 (as applicable, the “Separation Date”), the Executive will
terminate his employment with the Company as President and Chief Executive Officer and resign as a
member of the Board, and will no longer be an employee of the Company and will terminate from all
other positions he holds with or at the direction of the Company, whether as an officer, director,
manager, committee member or otherwise, including, but not limited to, his officer and board
position with Exterran GP LLC.

     2. Transition Period. Starting on the Effective Date and ending on the Separation
Date (the “Transition Period”), except as otherwise provided in this Section 2, the Executive will
continue to be employed as the President and Chief Executive Officer of the Company and will
continue to serve as a member of the Board. The foregoing notwithstanding, prior to October 10,
2011, the Board may, in its sole discretion, reassign the Executive to another position in the
Company (in which case he will be longer be the President and Chief Executive Officer as of such
reassignment date). In such an event, the parties agree that the Separation Date will be October
10, 2011.

     (a) Duties and Responsibilities. During the Transition Period, the
Executive’s duties and responsibilities shall be consistent with the Executive’s current (or
reassigned) positions and authorities. The Executive shall undertake to perform the
Executive’s

 

 

duties and responsibilities for the Company in good faith, on a full-time basis and to
the best of his abilities.

     (b) Compensation and Other Benefits Generally. During the Transition
Period, the Executive’s annual base salary shall be no less than the annual base salary the
Executive receives immediately prior to the Effective Date, and the Executive’s benefits and
perquisites shall be the same as those he and his eligible dependents were receiving
immediately prior to the Effective Date. The Executive’s compensation shall be payable
pursuant to the Company’s normal payroll practices for its executives, and shall be subject
to withholding for federal, state, city or other taxes as may be required pursuant to any
law or governmental regulation or ruling, all as consistent with current practices.

     (c) Employee Benefit Plans and Vacation. During the Transition Period, the
Executive shall be eligible to continue to participate in the employee benefit plans,
programs and policies maintained by the Company to which the Executive was eligible
immediately prior to the Effective Date. The Executive shall be entitled to use his accrued
vacation time during the Transition Period.

     3. Severance and Other Entitlements. In consideration for the Executive’s
execution of this Agreement, including the provisions in Section 4 of this Agreement, and subject
to the execution of the Waiver and Release attached hereto as Attachment A (the “Waiver”),
without revocation (as described in Section 3(e) below), the Company and the Executive agree as
follows:

     (a) Accrued Obligations. The Company shall pay to the Executive his base
salary earned, but unpaid, and earned but unused vacation days and any unreimbursed business
expenses, as of the Separation Date (“Accrued Obligations”), in accordance with its normal
payroll practice, but in no event later than 30 days following the Separation Date.

     (b) Severance Payment. The Company shall pay the Executive a lump sum
amount of $1,225,000 (“Severance Payment”) on the 45th day after the Separation
Date, subject to the Waiver requirement described in Section 3(e) below. The parties agree
that 90% of the Severance Payment shall be consideration for the restrictive covenants set
forth in Section 4 of this Agreement (the “Restrictive Covenant Consideration”).

     (c) Equity. The Executive’s (i) restricted stock and 2010 performance shares granted under the Amended and Restated Exterran Holdings, Inc. 2007 Stock Incentive
Plan (“2007 SIP”) and (ii) as previously approved by the Compensation Committee of the Board
of Directors of Exterran GP LLC, phantom units granted under the Exterran Partners, L.P.
Long-Term Incentive Plan, will be fully vested as of the Separation Date and paid or
delivered in accordance with the terms of the applicable award agreements. A list of the
Executive’s outstanding equity awards is attached hereto as Schedule I.

     (d) Medical Benefits. During the period commencing on the Separation Date
and ending on the earlier of (i) the fifth (5th) anniversary of the Separation
Date or (ii) the date the Executive and his eligible dependents are eligible for coverage
under a comparable medical plan of a subsequent employer of the Executive, the Executive and

-2-

 

his eligible dependents will be eligible to continue to be covered under the Company’s
medical plan as in effect during such period, subject to the Executive’s timely payment of
the plan premiums, at the active employee rates as in effect from time to time during such
period, and will continue to be covered under the Medical Expense Reimbursement Plan
(“MERP”). The foregoing notwithstanding, the Company may amend, modify or terminate either
plan, without the consent of the Executive. The parties further agree that any such action
by the Company (including the termination of the MERP) will not be a breach of this
Agreement by the Company nor will it entitle the Executive to any payment or replacement
benefits. The Executive acknowledges that the portion of the premiums paid by the Company
(or an affiliate of the Company) is taxable income to the Executive and the Company (or an
affiliate) will report such portion of the premiums as imputed income to the Executive on
the applicable IRS tax reporting forms.

     (e) Waiver. The foregoing to the contrary notwithstanding, the Executive’s
entitlement to the payment and benefits described in this Section 3, other than the Accrued
Obligations provided in Section 3(a) and the payments and entitlements described in Section
3(f) hereof (solely for purposes of this Section 3(e), the “Excluded Payments”), are subject
to, and contingent upon the Executive’s binding execution, without revocation during the
seven-day revocation period following execution, of the Waiver within 30 days of the
Separation Date (but not before the Separation Date). The parties hereto acknowledge that
the consideration to be provided under this Section 3 includes, in part, consideration for
the Waiver. The Company’s obligation to make any payments otherwise due under this Section
3, other than the Excluded Payments, shall cease in the event the Executive fails to execute
the Waiver within the time period set forth herein, and thus the Executive shall not be
entitled to any of the payments and entitlements provided in this Section 3 other than the
Excluded Payments. No payments shall be made until the expiration of the seven-day
revocation period following the Executive’s execution of the Waiver (the “Waiver Effective
Date”). Regardless of whether the Executive executes the Waiver, the Executive is entitled
to elect COBRA coverage under the Company’s group health plan continuation coverage for
himself and his covered dependents, subject to Executive’s payment of the full COBRA cost
and without any reimbursement by the Company or any portion of that cost.

     (f) Other Benefits. Nothing herein shall be deemed to affect the
Executive’s rights to any accrued and/or vested benefits as of the Separation Date,
including, without limitation, pursuant to any deferred compensation plan or program, the
Company’s Employee Stock Purchase Plan or the Company’s 401(k) plan, in accordance with the
terms and conditions of the applicable agreements, plans and programs for such benefits, and
the Company confirms that any matching Company contributions under the Company’s 401(k) and
the deferred compensation plan made on behalf to the Executive are fully vested. The
Executive’s deferred compensation balance as of August 1, 2011, and the payment date are set
forth on Schedule II attached hereto.

     4. Restrictive Covenants. As a material inducement to the Company to enter into
this Agreement and, in exchange for the Restrictive Covenant Consideration and any additional
equity benefits provided in Section 3(c) hereof to the Executive, the Executive agrees to the
provisions of Section 4. For purposes of this Section 4, the term “Company” means the Company, any
affiliate or subsidiary of the Company.

-3-

 

     (a) Confidentiality. The Executive recognizes and acknowledges that during
the course of the Transition Period and during his employment with the Company and as a
result of the position of trust he has held with the Company he has obtained private or
confidential information and proprietary data relating to the Company including, without
limitation, designs, ideas, concepts, improvements, product developments, discoveries and
inventions, whether patentable or not, that are conceived, made, developed or acquired by
the Executive, individually or in conjunction with others, during his employment with the
Company (whether during business hours or otherwise and whether on the Company’s premises or
otherwise) that relate to the Company’s businesses or properties, products or services
(including, without limitation, all such information relating to corporate opportunities,
business plans, strategies for developing business and market share, research, financial and
sales data, pricing terms, evaluations, opinions, interpretations, acquisition prospects,
the identity of customers or suppliers or their respective requirements, the identity of key
contacts within customers’ or suppliers’ organizations or within the organization of
acquisition prospects, or marketing and merchandising techniques, prospective names and
marks) and other data which are valuable assets and property rights of the Company. All of
such private or confidential information and proprietary data is referred to herein as
“Confidential Information;” provided, however, that Confidential Information will not
include any information known generally to the public or within the relevant trade or
industry (other than as a result of unauthorized disclosure by the Executive). The
Executive agrees that, other than in the ordinary course of performing his duties for the
Company or any affiliate (including, without limitation, Exterran Partners, L.P.), he will
not at any time, directly or indirectly, disclose or use Confidential Information except
with the prior written consent of the Board. Notwithstanding the foregoing, nothing herein
or otherwise shall prevent the Executive from disclosing any Confidential Information (i)
when disclosure is required by law or by any court, arbitrator, mediator or administrative
or legislative body (including any committee thereof) with apparent or actual jurisdiction
to order the Executive to disclose or make accessible any information, subject to the
Executive providing the Company with prior written notice of such disclosure unless such
notice is expressly prohibited by law, (ii) to the limited extent required, with respect to
any litigation, arbitration or mediation involving this Agreement or any other agreement
between the Company, Exterran Partners, L.P. or any of their affiliates and the Executive,
or (iii) in connection with any assistance provided by the Executive pursuant to Section 6
of this Agreement.

     (b) Non-Solicitation. Except with the written consent of the Board, the
Executive agrees that he will not (i) during the Transition Period and for two (2) years
after the Separation Date, in the Executive’s individual capacity or on behalf of another,
hire or offer to hire any of the officers, employees or directors of the Company, or
persuade or attempt to persuade in any manner any officers, employees or directors of the
Company to discontinue any employment relationship with the Company, or (ii) during the
Transition Period and for two (2) years after the Separation Date, solicit for a Restricted
Business, or divert or attempt to divert away to a Restricted Business any customer or
supplier of the Company which was a customer or supplier at the time of such solicitation or
diversion or attempted solicitation or diversion. Nothing herein, however, shall prohibit
the Executive from providing a personal reference for an employee in connection with any
educational pursuits.

-4-

 

     (c) Non-Competition. During the Transition Period and for a two (2)-year
period following the Separation Date, the Executive shall not, directly or indirectly:

     (i) engage in any managerial, executive, administrative, advisory,
consulting, operational or sales activities in a Restricted Business (as defined
below) anywhere in the Restricted Area (as defined below), including, without
limitation, as a director or partner of such Restricted Business, or

     (ii) organize, establish, operate, own, manage, control or have a direct or
indirect investment or ownership interest in a Restricted Business or in any
corporation, partnership (limited or general), limited liability company, enterprise
or other business entity that engages in a Restricted Business anywhere in the
Restricted Area.

     Nothing contained in this Section 4(c) shall prohibit or otherwise restrict the
Executive from continuing to serve as a member of the board of directors of Copano LLC or
from acquiring or owning, directly or indirectly, for passive investment purposes not
intended to circumvent this Agreement, securities of any entity engaged, directly or
indirectly, in a Restricted Business if either (i) such entity is a public entity and the
Executive (A) is not a controlling Person (as defined below) of, or a member of a group that
controls, such entity and (B) owns, directly or indirectly, no more than 3% of any class of
equity securities of such entity or (ii) such entity is not a public entity and the
Executive (x) is not a controlling Person of, or a member of a group that controls, such
entity and (y) does not own, directly or indirectly, more than 1% of any class of equity
securities of such entity. Notwithstanding the foregoing or otherwise, the Executive shall
not be prevented, following the Separation Date, from providing services to, having an
equity or other ownership interest in, or receiving compensation from any entity which is,
or is a general partner in, or manages or participates in managing a public or private fund
(including any private equity and/or hedge fund) or other investment vehicle which has an
interest in or manages a Restricted Business; provided, however, that in all cases the
Executive does not directly or indirectly provide any services to, nor is in any other way
involved in the management or business of, the Restricted Business.

     For purposes of Section 4(b) and this Section 4(c):

“Restricted Area” shall mean any state in the United States, or any country in which
the Company or its subsidiaries engages in such Restricted Business as of the
Separation Date;

“Restricted Business” shall mean the business of designing, manufacturing,
servicing, operating, marketing, assembling, renting or leasing of air or gas
compressors or devices using comparable technologies or other business in which the
Company is engaged in on the Separation Date. To the extent that any entity is
primarily engaged in a business other than a Restricted Business, the term
“Restricted Business” shall mean the operations, division, segment or subsidiary of
such entity that is engaged in any Restricted Business; and

-5-

 

“Person” shall mean any individual, entity or group (within the meaning of Section
13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended.

     (d) Nondisparagement. The Executive, acting alone or in concert with
others, agrees that from and after the Separation Date he will not publicly criticize or
disparage the Company, or privately criticize or disparage the Company in a manner intended
or reasonably calculated to result in public embarrassment to, or injury to the reputation
of, the Company; provided, however, that nothing in this Agreement shall apply to or
restrict in any way the communication of information by the Executive to any state or
federal law enforcement or regulatory agency or any legislative or regulatory committee or
require notice to the Company thereof. The Company agrees that it will instruct its senior
management and directors not to publicly criticize or disparage the Executive, or privately
criticize or disparage the Executive in a manner intended or reasonably calculated to result
in public embarrassment to, or injury to the reputation of, the Executive.

     (e) Enforcement. The Executive hereby agrees that a violation of the
provisions of this Section 4 by the Executive would cause irreparable injury to the Company,
for which it would have no adequate remedy at law. Any controversy or claim arising out of
or relating to the provisions of this Section 4, or any alleged breach of Section 4, shall
be settled by binding arbitration in accordance with Section 9. Notwithstanding the
foregoing, however, the Company specifically retains the right before, during or after the
pendency of any arbitration to seek injunctive relief from a court having jurisdiction for
any actual or threatened breach of this Section 4 without necessity of complying with any
requirement as to the posting of a bond or other security (it being understood that the
Executive hereby waives any such requirement). Any such injunctive relief shall be in
addition to any other remedies to which the Company may be entitled at law or in equity or
otherwise, and the institution and maintenance of an action or judicial proceeding for, or
pursuit of, such injunctive relief shall not constitute a waiver of the right of the Company
to submit the dispute to arbitration. Notwithstanding anything to the contrary in this
Agreement, the payments, benefits and entitlements provided to the Executive by the Company
(including Exterran Partners, L.P.) shall only be subject to forfeiture or recoupment as
follows: if the Executive breaches Section 4(a), (b) or (c) of this Agreement, then the
Company shall have the right to cease the payments and benefits provided under Section 3(b)
and Section 3(c) of this Agreement (including, but not limited to, the Restrictive Covenant
Consideration) or require repayment of such payments and benefits if they have already been
paid or distributed; provided, however, that first the Company shall provide the Executive
with written notice of any alleged breach.

     (f) Interpretation. If any provision of this Section 4 is found by a court
of competent jurisdiction to be unreasonably broad, oppressive or unenforceable, such court
(i) shall narrow the scope of this Agreement in order to ensure that the application thereof
is not unreasonably broad, oppressive or unenforceable and (ii) to the fullest extent
permitted by law, shall enforce such Agreement as though reformed.

-6-

 

     (g) Other Agreements. Except as otherwise expressly set forth in this
Section 4, there are no other restrictions on the Executive’s activities following the
Separation Date.

     5. Return of Property. On or immediately following the Separation Date, the
Executive shall promptly return all Property (as hereinafter defined) which had been entrusted or
made available to the Executive by the Company; provided that if such Property is in electronic
form the Executive shall be deemed to comply with this Section 5 if he deletes such Property from
his computers. The term “Property” shall mean all records, files, memoranda, reports, keys, codes,
computer hardware and software, documents, videotapes, written presentations, brochures, drawings,
notes, correspondence, manuals, models, specifications, computer programs, e-mail, voice mail,
electronic databases, maps, drawings, architectural renditions and all other writings or materials
of any type and other property of any kind or description (whether in electronic or other form)
prepared, used or possessed by the Executive during his employment by the Company (and any
duplicates of any such property) together with any and all information, ideas, concepts,
discoveries, and inventions and the like conceived, made, developed or acquired at any time by the
Executive individually or with others during his employment which relate to the Company’s business,
products or services. Notwithstanding anything to the contrary, the Executive shall be entitled to
retain his personal papers and information he reasonably believes are necessary for tax purposes.

     6. Post-Separation Date Assistance. Following the Separation Date, the Executive
agrees that he will reasonably and appropriately respond to all inquiries from the Company relating
to any current or future litigation of which he may have relevant information, and shall make
himself reasonably available to confer with the Company and otherwise provide testimony as the
Company may deem necessary in connection with such litigation, subject in all cases to his other
business and personal commitments. Such assistance shall not exceed 5 days per year and shall be
provided by the Executive without remuneration, but the Company shall pay or reimburse the
Executive for all reasonable expenses actually incurred or paid by the Executive in complying with
this Section 6 upon the presentation of expense statements or vouchers or such other supporting
information as the Company may reasonably require of the Executive.

     7. Assignment. This Agreement and all of the Company’s rights and obligations
hereunder shall not be assignable by the Company without the Executive’ prior written consent
except as incident to a reorganization, merger or consolidation, or transfer of all or
substantially all of the Company’s assets. The Executive may not assign this Agreement or any of
his rights and obligations under this Agreement without the prior written consent of the Company.
If the Executive should die prior to payment of the Severance Payment, such payment shall be paid
to his estate; any other payment, entitlement or benefit that is due to him under this Agreement
shall be paid as provided under the terms of the applicable plan, program or agreement. Subject to
the foregoing, this Agreement shall be binding on, and inure to the benefit of, the Company and the
Executive and their respective successors and assigns.

     8. No Waiver. No term or condition of this Agreement shall be deemed to have been
waived, nor shall there be an estoppel against the enforcement of any provision of this Agreement,
except by written instrument of the party charged with such waiver or estoppel.

     9. Arbitration. Any dispute, controversy or claim arising out of or relating to
the obligations under this Agreement, shall be settled by final and binding arbitration in
accordance

-7-

 

with the American Arbitration Association Employment Dispute Resolution Rules. The arbitrator
shall be selected by mutual agreement of the parties, if possible. If the parties fail to reach
agreement upon appointment of an arbitrator within 30 days following receipt by one party of the
other party’s notice of desire to arbitrate, the arbitrator shall be selected from a panel or
panels submitted by the American Arbitration Association (the “AAA”). The selection process shall
be that which is set forth in the AAA Employment Dispute Resolution Rules, except that, if the
parties fail to select an arbitrator from one or more panels, AAA shall not have the power to make
an appointment but shall continue to submit additional panels until an arbitrator has been
selected. Either party may appeal the arbitration award and judgment thereon and, in actions
seeking to vacate an award, the standard of review to be applied to the arbitrator’s findings of
fact and conclusions of law will be the same as that applied by an appellate court reviewing a
decision of a trial court sitting without a jury. This agreement to arbitrate shall not preclude
the parties from engaging in voluntary, non-binding settlement efforts including mediation. All
fees and expenses of the arbitration, including a transcript if requested but not including the
legal costs and fees incurred by any party to such arbitration, will be borne by the parties
equally. Each party shall be responsible for its own legal costs and fees.

     10. Notices. All notices or communications hereunder shall be in writing,
addressed as follows:

To the Company:

Exterran Holdings, Inc.

16666 Northchase Drive

Houston, TX 77060

Attention: General Counsel

To the Executive:

Mr. Ernie L. Danner

60 Autumn Crescent

The Woodlands, TX 77381

All such notices shall be conclusively deemed to be received and shall be effective; (i) if sent by
hand delivery or by overnight delivery service, upon receipt, (ii) if sent by telecopy or facsimile
transmission, upon confirmation of receipt by the sender of such transmission or (iii) if sent by
registered or certified mail, on the fifth (5th) day after the day on which such notice
is mailed.

     11. No Mitigation/No Offset. The Executive shall be under no duty to mitigate
damages by seeking other employment and there shall be no offset or recoupment with respect to any
payments or benefits provided to the Executive under this Agreement on account of any remuneration
received by the Executive from any subsequent employment.

     12. Indemnification/D&O Coverage. During the Transition Period and thereafter,
the Executive shall continue to be indemnified and advanced expenses in accordance with the
indemnification agreement between the Executive and the Company dated as of August 20, 2007 and
shall continue to be covered under any applicable directors’ and officers’ liability insurance

-8-

 

policies, as may be in effect from time to time, on the same basis as members of the Board are
so covered.

     13. Tax Withholding. The Company may withhold from any amounts payable under this
Agreement all federal, state, city or other taxes that will be required pursuant to any law or
governmental regulation or ruling.

     14. Severability. If any provision of this Agreement is held to be invalid,
illegal or unenforceable, in whole or part, such invalidity will not affect any otherwise valid
provision, and all other valid provisions will remain in full force and effect.

     15. Counterparts. This Agreement may be executed in two or more counterparts,
each of which will be deemed an original, and all of which together will constitute one document.

     16. Titles. The titles and headings preceding the text of the paragraphs and
subparagraphs of this Agreement have been inserted solely for convenience of reference and do not
constitute a part of this Agreement or affect its meaning, interpretation or effect.

     17. Governing Law. This Agreement will be construed and enforced in accordance
with the laws of the State of Texas.

     18. Venue. Except as provided in Section 9, any suit, action or other legal
proceeding arising out of this Agreement shall be brought in the United States District Court for
the Southern District of Texas, Houston Division, or, if such court does not have jurisdiction or
will not accept jurisdiction, in any court of general jurisdiction in Harris County, Texas. Each
of the Executive and the Company consents to the jurisdiction of any such court in any such suit,
action, or proceeding and waives any objection that it may have to the laying of venue of any such
suit, action, or proceeding in any such court.

     19. Section 409A. Payments pursuant to this Agreement are intended to comply with
or be exempt from Section 409A of the Code and accompanying regulations and other binding guidance
promulgated thereunder (“Section 409A”), and the provisions of this Agreement will be administered,
interpreted and construed accordingly. Whenever payments under this Agreement are to be made in
installments, each such installment shall be deemed to be a separate payment for purposes of
Section 409A.

          All reimbursements provided under this Agreement shall be made or provided in accordance with
the requirements of Section 409A, including, where applicable, the requirement that (i) any
reimbursement shall be for expenses incurred during the Executive’s lifetime (or during a shorter
period of time specified in this Agreement), (ii) the amount of expenses eligible for reimbursement
during a calendar year may not affect the expenses eligible for reimbursement in any other calendar
year, (iii) the reimbursement of an eligible expense will be made on or before the last day of the
calendar year following the year in which the expense is incurred, and (iv) the right to
reimbursement is not subject to liquidation or exchange for another benefit.

          Notwithstanding any provision of this Agreement to the contrary, the Company and the Executive
agree that any benefit or benefits under this Agreement that the Company determines are subject to
the suspension period under Section 409A(a)(2)(B) of the Code shall

-9-

 

not be paid or commence until the first business day next following the earlier of (i) the date that
is six (6) months and one day following the date of the Executive’s termination of employment,
(ii) the date of the Executive’s death or (iii) such earlier date as complies with the requirements
of Section 409A.

     20. Entire Agreement. Each party acknowledges that this Agreement is the complete
and exclusive statement of the agreement between the parties regarding the subject matter herein
and supersedes any other oral or written agreements between the parties with respect to the subject
matter hereof; provided, however, that the Change of Control Agreement between the Company and the
Executive dated October 8, 2008 (the “Change of Control Agreement”) shall remain in full force and
effect through the Separation Date, subject to the modification provided below (and if there is
Qualifying Termination under such agreement, then the Change of Control Agreement shall apply in
lieu of this Agreement (and this Agreement shall be of no further force and effect)). The
foregoing notwithstanding, as of the Effective Date, clause (b) of the definition of a “Change of
Control” in the Change of Control Agreement (regarding a change in composition of the Board) shall
no longer apply and thus such a change in the composition of the Board shall not constitute a
Change of Control under the Change of Control Agreement (and the parties agree and acknowledge that
the Change of Control Agreement is hereby amended consistent with the foregoing). This Agreement
may not be modified or altered except by a written instrument duly executed by both parties.

[Execution Page Follows]

-10-

 

          IN WITNESS WHEREOF, the parties have executed this Agreement in multiple counterparts, all of
which shall constitute one agreement, on the dates specified below.

	 	 	 	 	 
	 	EXTERRAN HOLDINGS, INC.

 	 
	 	By:  	 	 
	 	 	Gordon T. Hall 	 
	 	 	Chairman, Board of Directors

Exterran Holdings, Inc.	 
	 	

Date: August 3, 2011	 
	 

	 	 	 	 	 
	 	EXECUTIVE

Ernie L. Danner

Date: ________________, 2011

 	 

-11-

 

Attachment A

WAIVER AND RELEASE

          In exchange for the consideration offered under the Separation Agreement between me and
Exterran Holdings, Inc. (the “Company”), dated effective August __, 2011 (the “Agreement”), I
hereby waive all of my claims and release the Company, any affiliate, subsidiary or venture of the
Company, including, but not limited to, Exterran Partners, LP and Exterran GP LLC, and any of their
respective officers, directors, employees, partners, investors, counsel or agents, their benefit
plans and the fiduciaries and agents of said plans (but with respect to any individual, agent or
plan or fiduciary, only in connection with his or its official capacity with the Corporate Group
and not in any individual capacity unrelated to the Corporate Group or to my employment or
directorship with the Company Group), collectively referred to as the “Corporate Group”) from any
and all claims, demands, actions, liabilities and damages except for those claims not released by
me herein.

          I understand that signing this Waiver and Release is an important legal act. I acknowledge
that the Company has advised me in writing to consult an attorney before signing this Waiver and
Release. I understand that I have at least 21 calendar days to consider whether to sign and return
this Waiver and Release to the Company by first-class mail or by hand delivery in order for it to
be effective.

          In exchange for the consideration offered to me by the Agreement, which I acknowledge provides
consideration to which I would not otherwise be entitled, I agree not to sue or file any charges of
discrimination, or any other action or proceeding with any local, state and/or federal agency or
court regarding or relating in any way to the Company with respect to the claims released by me
herein, and I knowingly and voluntarily waive all claims and release the Corporate Group from any
and all claims, demands, actions, liabilities, and damages, whether known or unknown, arising out
of or relating in any way to the Corporate Group, except with respect to rights under the
Agreement, rights under employee benefit plans or programs other than those specifically addressed
in the Agreement, and such rights or claims as may arise after the date this Waiver and Release is
executed. This Waiver and Release includes, but is not limited to, claims and causes of action
under: Title VII of the Civil Rights Act of 1964, as amended; the Age Discrimination in Employment
Act of 1967, as amended, including the Older Workers Benefit Protection Act of 1990; the Civil
Rights Act of 1866, as amended; the Civil Rights Act of 1991; the Americans with Disabilities Act
of 1990; the Energy Reorganization Act, as amended, 42 U.S.C. § 5851; the Workers Adjustment and
Retraining Notification Act of 1988; the Pregnancy Discrimination Act of 1978; the Employee
Retirement Income Security Act of 1974, as amended; the Family and Medical Leave Act of 1993; the
Fair Labor Standards Act; the Occupational Safety and Health Act; claims in connection with
workers’ compensation or “whistle blower” statutes; and/or contract, tort, defamation, slander,
wrongful termination or any other state or federal regulatory, statutory or common law. Further, I
expressly represent that no promise or agreement which is not expressed in the Agreement or this
Waiver and Release has been made to me in executing this Waiver and Release, and that I am relying
on my own judgment in executing this Waiver and Release, and that I am not relying on any statement
or representation of any member of the Corporate Group or any of their agents. I agree
that this Waiver and Release is valid, fair, adequate and reasonable, is with my full knowledge and
consent, was not procured through fraud, duress or mistake and has not had the effect of
misleading, misinforming or failing to inform me. I acknowledge and agree that the Company

A-1

 

will withhold any taxes required by law from the amount payable to me under the Agreement and
that such amount shall be reduced by any monies owed by me to the Company.

          This Waiver and Release includes a release of claims of discrimination or retaliation on the
basis of workers’ compensation status, but does not include workers’ compensation claims. Excluded
from this Waiver and Release are any claims which by law cannot be waived in a private agreement
between an employer and employee, including but not limited to claims under the Fair Labor
Standards Act and the right to file a charge with or participate in an investigation conducted by
the Equal Employment Opportunity Commission (“EEOC”) or any state or local fair employment
practices agency. I waive, however, the right to any monetary recovery or other relief should the
EEOC or any other agency pursue a claim on my behalf.

          Notwithstanding the foregoing, I do not release and expressly retain (a) all rights to
indemnity, contribution, advancement of expenses and a defense, and directors and officers and
other liability coverage that I may have under any statute, the bylaws of the Company or by other
agreement; and (b) the right to any unpaid reasonable business expenses and any accrued benefits
payable under any Company welfare plan, tax-qualified plan or other Benefit Plans. For the
avoidance of doubt, the term “Benefit Plans” includes any outstanding equity awards under an equity
incentive plan, any deferred compensation plan, the Company’s Employee Stock Purchase Plan and the
Company’s 401(k) plan.

          Should any of the provisions set forth in this Waiver and Release be determined to be invalid
by a court, agency or other tribunal of competent jurisdiction, it is agreed that such
determination shall not affect the enforceability of other provisions of this Waiver and Release.

          I understand that for a period of seven calendar days following my signing this Waiver and
Release (the “Waiver Revocation Period”), I may revoke my acceptance of the offer by delivering a
written statement to the Company by hand or by registered mail, addressed to the address for the
Company specified in the Agreement, in which case the Waiver and Release will not become effective.
In the event I revoke my acceptance of this offer, the Company shall have no obligation to provide
me the consideration offered under the Agreement to which I would not otherwise have been entitled.
I understand that failure to revoke my acceptance of the offer within the Waiver Revocation Period
will result in this Waiver and Release being permanent and irrevocable.

          I acknowledge that I have read this Waiver and Release, have had an opportunity to ask
questions, have it explained to me and had the opportunity to seek independent legal advice
with respect to the matters addressed in this Waiver and Release and that I understand
that this Waiver and Release will have the effect of knowingly and voluntarily waiving any action I
might pursue, including breach of contract, personal injury, retaliation, discrimination on the
basis of race, age, sex, national origin or disability and any other claims arising prior to the
date of this Waiver and Release, except for those claims specifically not released by me herein.

          By execution of this document, I do not waive or release or otherwise relinquish any legal
rights I may have which are attributable to or arise out of acts, omissions or events of the
Company or any other member of the Corporate Group which occur after the date of execution of this
Waiver and Release.

A-2

 

	 	 	 

	AGREED TO AND ACCEPTED this

______ day of _______________, 201__
	 	 
	 
	 
	 	 
	 

ERNIE L. DANNER

	 	 

A-3

 

Schedule I

Outstanding Equity Awards as of August 3, 2011.

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Date of	 	 	 	 	 	 	Grant	 	 	 	 	 	 	 
	Award Type	 	Grant	 	 	Total Award	 	 	Price	 	 	Vested	 	 	Unvested	 
	 
	Options
	 	 	4/30/2004	 	 	 	25,000	 	 	$	30.07	 	 	 	21,675	 	 	 	—	 
	 
	 	 	3/9/2005	 	 	 	22,000	 	 	$	38.15	 	 	 	22,000	 	 	 	—	 
	 
	 	 	3/3/2006	 	 	 	25,000	 	 	$	43.39	 	 	 	25,000	 	 	 	—	 
	 
	 	 	10/8/2008	 	 	 	103,217	 	 	$	23.63	 	 	 	68,812	 	 	 	34,405	 
	 
	 	 	3/4/2009	 	 	 	74,548	 	 	$	16.14	 	 	 	49,699	 	 	 	24,849	 
	 
	 	 	2/28/2010	 	 	 	118,785	 	 	$	22.75	 	 	 	39,595	 	 	 	79,190	 
	 
	 	 	2/28/2010	 	 	 	51,645	 	 	$	22.75	 	 	 	17,215	 	 	 	34,430	 
	 
	 	 	3/4/2011	 	 	 	124,602	 	 	$	22.82	 	 	 	—	 	 	 	124,602	 
	 	 	 
	 
	 	 	 	 	 	 	544,797	 	 	 	 	 	 	 	243,996	 	 	 	297,476	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Restricted Stock
	 	 	3/4/2009	 	 	 	27,881	 	 	 	 	 	 	 	18,588	 	 	 	9,293	 
	 
	 	 	2/28/2010	 	 	 	45,495	 	 	 	 	 	 	 	15,165	 	 	 	30,330	 
	 
	 	 	2/28/2010	 	 	 	19,780	 	 	 	 	 	 	 	6,594	 	 	 	13,186	 
	 
	 	 	3/4/2011	 	 	 	45,355	 	 	 	 	 	 	 	—	 	 	 	45,355	 
	 	 	 
	 
	 	 	 	 	 	 	138,511	 	 	 	 	 	 	 	40,347	 	 	 	98,164	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Performance Shares
	 	 	2/28/2010	 	 	 	37,363	 	 	 	 	 	 	 	 	 	 	 	37,363	 
	 	 	 
	 
	 	 	 	 	 	 	37,363	 	 	 	 	 	 	 	—	 	 	 	37,363	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	EXLP Phantom Units
	 	 	3/4/2009	 	 	 	8,584	 	 	 	 	 	 	 	5,723	 	 	 	2,861	 
	 
	 	 	2/28/2010	 	 	 	10,052	 	 	 	 	 	 	 	3,351	 	 	 	6,701	 
	 
	 	 	2/28/2010	 	 	 	4,371	 	 	 	 	 	 	 	1,457	 	 	 	2,914	 
	 
	 	 	3/4/2011	 	 	 	8,070	 	 	 	 	 	 	 	—	 	 	 	8,070	 
	 	 	 
	 
	 	 	 	 	 	 	31,077	 	 	 	 	 	 	 	10,531	 	 	 	20,546	 

A-4

 

Schedule II

Deferred Compensation Balance as of August 1, 2011 and Payment Date

	 	 	 

	Balance:

	 	 $485,135.21 (this amount is subject to change based on investment
earnings and losses incurred after 08/01/2011).
	 
	 	 
	Payment:

	 	Per the Plan terms, lump sum payment 6 months following the
Executive’s termination (or, if earlier, the Executive’s death).

A-5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00192-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00192-of-00352.parquet"}]]